In alignment with the Trump administration’s efforts to lower drug prices, Amgen today launched AmgenNow, a direct-to-patient program offering evolocumab (Repatha) at a monthly price of $239, nearly ...
The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.
Clinical Trials Arena on MSN
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial
Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without ...
Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a ...
Madrid, Spain – 1 September 2025: After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to ...
GlobalData on MSN
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback